The final terms total $399,998,279.17 in shares and pre-funded warrants before underwriting discounts. The offering was expected to close on or about June 15, 2026.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $135.5 million, plus short-term investments of $759.6 million, $895.2 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Enliven Therapeutics
Has Enliven Therapeutics raised money recently?
Our latest story on this, dated Jun 11, 2026: "Enliven Therapeutics launches $250,000,000 offering, then prices upsized sale at $37.50". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Enliven Therapeutics?
Enliven Therapeutics, Inc. trades under the ticker ELVN on NASDAQ.
Where is Enliven Therapeutics listed?
Enliven Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Enliven Therapeutics?
The SEC Central Index Key (CIK) for Enliven Therapeutics, Inc. is 1672619. Its filings are on SEC EDGAR.
How many shares does Enliven Therapeutics have outstanding?
73,270,761 shares as of 2026-07-28, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Enliven Therapeutics listed under?
Our directory records Enliven Therapeutics, Inc. under United States.
What does Enliven Therapeutics do?
Our directory classifies Enliven Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Enliven Therapeutics?
The ISIN recorded for Enliven Therapeutics, Inc. is US29337E1029.
Does aibio.space cover Enliven Therapeutics?
aibio.space lists Enliven Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Enliven Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Enliven Therapeutics profitable?
Enliven Therapeutics, Inc. reported a net loss of $103.7 million for the fiscal year ended Dec 31, 2025, and used $70.3 million of cash in operations, per its annual report to the SEC.
How much does Enliven Therapeutics spend on research and development?
$85.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Enliven Therapeutics have?
$895.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Enliven Therapeutics (ELVN) stock news?
Our latest story on Enliven Therapeutics, dated Jun 11, 2026: "Enliven Therapeutics launches $250,000,000 offering, then prices upsized sale at $37.50". The final terms total $399,998,279.17 in shares and pre-funded warrants before underwriting discounts. The offering was expected to close on or about June 15, 2026. Source.
What is Enliven Therapeutics's market cap?
We do not publish live share prices. In its annual report, Enliven Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $836.0 million as of Jun 30, 2025.
Investor discussion: Enliven Therapeutics
Members talk about Enliven Therapeutics (ELVN). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Enliven Therapeutics, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ELVN on TradingView.
SEC filings and registration
SEC name
Enliven Therapeutics, Inc.
CIK
1672619
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
ELVN (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer
Business address
205 PARK ROAD, BURLINGAME, CA, 94010
Phone
650-547-5814
Shares outstanding
73,270,761 as of 2026-07-28 (10-Q filed 2026-08-05)
Former names
IMARA Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Enliven Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ELVN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio